益生菌对肝硬化血氨影响的实验及临床研究  

Experimental and clinical study of BIFICO on plasma ammonia in rats and patients with liver cirrhosis

作　　者：卜淑蕊[1] 戴鹏[2] 赵严[1] 刘近春[1] 闫柱[1] 

机构地区：[1]山西医科大学第一医院消化科,山西太原030001 [2]山西省肿瘤医院消化科,山西太原030000

出　　处：《中国微生态学杂志》2007年第1期25-26,共2页Chinese Journal of Microecology

摘　　要：目的采用动物实验及临床观察,探讨益生菌制剂培菲康治疗肝硬化高氨血症的作用机制。方法采用大鼠肝硬化模型,其中治疗组予以培菲康悬液每天灌胃治疗共8周,检测治疗组及对照组血浆内毒素指标;并选用70例肝硬化Child-Pugh分级为B级的患者,其中治疗组口服培菲康胶囊(每次2粒,每日3次)3周,观察治疗前后血浆内毒素变化。结果培菲康治疗组的肝硬化大鼠及患者血浆内毒素均明显低于对照组(P<0.05)。结论培菲康能明显降低肝硬化患者的血氨水平,可作为肝硬化患者的辅助用药。Objective To investigate the effect of Bifico capsule on the levels of plasma ammonia in rats and patients with liver cirrhosis. Methods 44 Wistar rats were induced into live cirrhosis models by injecting CCL4 every 3 days for 8 weeks. 70 patients with cirrhosis of Child-Pugh B stage were observed, 35 patients were treated by Bifieo capsule （2 capsules, triple daily） orally for three weeks. Plasma ammonia was detected before and after the therapy. Result The levels of plasma ammonia in the treatment group wes significantly lower than those in control group （P 〈 0. 05）. Conclusion Bifico can reduce the level of plasma ammonia in patients with liver cirrhosis, it can be used for routine auxiliary therapy on the liver cirrhosis.

关 键 词：培菲康 肝硬化 患者 大鼠 血氨 

分 类 号：R575.2[医药卫生—消化系统]